- Home
- BHVN vs MNKD Comparison
BHVN vs MNKD Comparison
Compare BHVN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHVN
- MNKD
- Stock Information
- Founded
- BHVN 2013
- MNKD 1991
- Country
- BHVN United States
- MNKD United States
- Employees
- BHVN N/A
- MNKD N/A
- Industry
- BHVN Biotechnology: Pharmaceutical Preparations
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- BHVN Health Care
- MNKD Health Care
- Exchange
- BHVN Nasdaq
- MNKD Nasdaq
- Market Cap
- BHVN 1.5B
- MNKD 1.2B
- IPO Year
- BHVN 2017
- MNKD 2004
- Fundamental
- Price
- BHVN $14.72
- MNKD $5.39
- Analyst Decision
- BHVN Strong Buy
- MNKD Strong Buy
- Analyst Count
- BHVN 16
- MNKD 5
- Target Price
- BHVN $52.13
- MNKD $10.80
- AVG Volume (30 Days)
- BHVN 2.0M
- MNKD 5.8M
- Earning Date
- BHVN 11-11-2025
- MNKD 11-06-2025
- Dividend Yield
- BHVN N/A
- MNKD N/A
- EPS Growth
- BHVN N/A
- MNKD 149.32
- EPS
- BHVN N/A
- MNKD 0.11
- Revenue
- BHVN N/A
- MNKD $301,736,000.00
- Revenue This Year
- BHVN N/A
- MNKD $16.36
- Revenue Next Year
- BHVN $2,195.07
- MNKD $20.34
- P/E Ratio
- BHVN N/A
- MNKD $50.42
- Revenue Growth
- BHVN N/A
- MNKD 21.48
- 52 Week Low
- BHVN $12.79
- MNKD $3.38
- 52 Week High
- BHVN $55.70
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- BHVN 49.97
- MNKD 63.64
- Support Level
- BHVN $13.41
- MNKD $5.25
- Resistance Level
- BHVN $14.23
- MNKD $5.77
- Average True Range (ATR)
- BHVN 0.86
- MNKD 0.29
- MACD
- BHVN -0.17
- MNKD -0.01
- Stochastic Oscillator
- BHVN 33.98
- MNKD 54.75
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.